ImmuPharma (LON:IMM) Stock Price Down 10% - Time to Sell?

Key Points

• ImmuPharma's stock price fell by 10%, trading at GBX 11.25 ($0.15) after reaching a low of GBX 10.51 ($0.14).
• The company's market capitalization is £56.23 million and it has a negative price-to-earnings ratio of -1,264.38.
• ImmuPharma reported a loss of GBX (0.38) earnings per share for the last quarter, with analysts forecasting an annual EPS of -339.00.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was down 10% during trading on Monday . The company traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares were traded during mid-day trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Price Performance

The stock has a fifty day moving average price of GBX 4.46 and a 200 day moving average price of GBX 3.33. The stock has a market capitalization of £56.23 million, a P/E ratio of -1,264.38 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.